ValuEngine upgraded shares of T2 Biosystems (NASDAQ:TTOO) from a strong sell rating to a sell rating in a research report released on Monday.
Other research analysts have also recently issued reports about the company. HC Wainwright set a $8.00 target price on T2 Biosystems and gave the stock a buy rating in a report on Wednesday, March 7th. Zacks Investment Research cut T2 Biosystems from a buy rating to a hold rating in a report on Saturday, January 6th. Finally, Goldman Sachs initiated coverage on T2 Biosystems in a report on Monday, January 29th. They set a neutral rating and a $5.20 target price on the stock. One analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company’s stock. T2 Biosystems currently has a consensus rating of Hold and an average price target of $5.66.
Shares of T2 Biosystems stock opened at $6.91 on Monday. The company has a quick ratio of 5.28, a current ratio of 5.40 and a debt-to-equity ratio of 2.25. T2 Biosystems has a twelve month low of $2.50 and a twelve month high of $7.26. The stock has a market capitalization of $241.82, a PE ratio of -3.64 and a beta of 1.49.
TRADEMARK VIOLATION WARNING: “T2 Biosystems (TTOO) Upgraded by ValuEngine to “Sell”” was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://stocknewstimes.com/2018/03/20/t2-biosystems-ttoo-upgraded-by-valuengine-to-sell.html.
About T2 Biosystems
T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.